Spots Global Cancer Trial Database for metastatic nsclc
Every month we try and update this database with for metastatic nsclc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | NCT05478538 | Non Small Cell ... Metastatic Non ... NSCLC Metastatic NSCL... | Core Needle or ... | 18 Years - | Elephas | |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | NCT04614103 | Metastatic Non ... | LN-145 LN-145 | 18 Years - 70 Years | Iovance Biotherapeutics, Inc. | |
| A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | NCT06159790 | Metastatic NSCL... | GME751 Keytruda-EU | 18 Years - | Sandoz | |
| Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6 | NCT06228482 | Metastatic Nons... | [68Ga]Ga DOTA-5... | 18 Years - | University of California, Davis | |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | NCT05361174 | Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm... | IOV-4001 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer | NCT05617313 | Non Small Cell ... Metastatic NSCL... Recurrent Non S... | Pembrolizumab GT103 | 18 Years - | Duke University | |
| Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers | NCT05091190 | Metastatic NSCL... Metastatic Head... | Blood draws | 18 Years - | Hospices Civils de Lyon | |
| Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy | NCT05715229 | Carcinoma, Non-... | Nivolumab Ipilimumab Carboplatin Paclitaxel Pemetrexed | 18 Years - | Hackensack Meridian Health | |
| AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC | NCT06068153 | Metastatic Non ... KRAS G12C | Sotorasib Lenvatinib | 18 Years - | ETOP IBCSG Partners Foundation | |
| Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer | NCT02250326 | Carcinoma, Non-... | nab-paclitaxel ... CC-486 Duravalumab | 18 Years - | Celgene | |
| Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC | NCT02175381 | NSCLC | Carboplatin Gemcitabine | 70 Years - | Hellenic Oncology Research Group | |
| Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC | NCT02179567 | NSCLC | Docetaxel Bevacizumab | 70 Years - | Hellenic Oncology Research Group | |
| Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC) | NCT04636775 | NSCLC Stage IV NSCLC, Recurren... | Microbiome | 18 Years - | University of Kansas Medical Center | |
| Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | NCT05478538 | Non Small Cell ... Metastatic Non ... NSCLC Metastatic NSCL... | Core Needle or ... | 18 Years - | Elephas | |
| Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy | NCT05715229 | Carcinoma, Non-... | Nivolumab Ipilimumab Carboplatin Paclitaxel Pemetrexed | 18 Years - | Hackensack Meridian Health | |
| A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | NCT06159790 | Metastatic NSCL... | GME751 Keytruda-EU | 18 Years - | Sandoz | |
| REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis | NCT06315010 | NSCLC Brain Metastase... ROS1 Gene Rearr... | Repotrectinib | 18 Years - | MedSIR | |
| GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC | NCT03417882 | Metastatic NSCL... | GRN-1201 + Pemb... | 18 Years - | BrightPath Biotherapeutics | |
| A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC) | NCT03353675 | Non Small Cell ... | TG4010 Chemotherapy Nivolumab | 18 Years - | Transgene | |
| SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation | NCT05480865 | Solid Tumor, Ad... Metastatic Soli... Metastatic NSCL... Non Small Cell ... | BBP-398 sotorasib | 18 Years - 99 Years | Navire Pharma Inc., a BridgeBio company | |
| NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | NCT03589339 | Radiotherapy Immunotherapy Microsatellite ... Metastasis From... Squamous Cell C... Metastasis From... Metastatic Rena... Metastasis From... Metastatic Trip... Metastatic NSCL... Metastasis From... | NBTXR3 SABR Nivolumab Pembrolizumab | 18 Years - | Nanobiotix | |
| Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT01395758 | Metastatic Non-... | ARQ 197 plus er... Pemetrexed, doc... | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy | NCT05715229 | Carcinoma, Non-... | Nivolumab Ipilimumab Carboplatin Paclitaxel Pemetrexed | 18 Years - | Hackensack Meridian Health | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC | NCT04846452 | Metastatic NSCL... Recurrent NSCLC Advanced Non-Sm... | Sintilimab + An... Sintilimab + An... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC) | NCT01083589 | Non-small Cell ... | Imatinib Mesyla... Docetaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Cabazitaxel in Relapsed and Metastatic NSCLC | NCT01852578 | NSCLC | Cabazitaxel | 18 Years - | Hellenic Oncology Research Group | |
| Patient's Whole Process Follow-up Management(HOPE-1) | NCT05339568 | Locally Advance... Metastatic NSCL... | Patients' whole... | 18 Years - | Qianfoshan Hospital | |
| Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC | NCT02175381 | NSCLC | Carboplatin Gemcitabine | 70 Years - | Hellenic Oncology Research Group | |
| Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer | NCT04940325 | Metastatic Lung... | DS-1062a | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers | NCT05091190 | Metastatic NSCL... Metastatic Head... | Blood draws | 18 Years - | Hospices Civils de Lyon | |
| Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy | NCT00702975 | Locally Advance... NSCLC | Paclitaxel, Car... | 18 Years - | Radboud University Medical Center | |
| Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer | NCT05403385 | Metastatic NSCL... Stage III NSCLC | inupadenant Placebo Carboplatin Pemetrexed | 18 Years - | iTeos Therapeutics | |
| Patient's Whole Process Follow-up Management(HOPE-1) | NCT05339568 | Locally Advance... Metastatic NSCL... | Patients' whole... | 18 Years - | Qianfoshan Hospital | |
| Patient's Whole Process Follow-up Management(HOPE-1) | NCT05339568 | Locally Advance... Metastatic NSCL... | Patients' whole... | 18 Years - | Qianfoshan Hospital | |
| NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | NCT03589339 | Radiotherapy Immunotherapy Microsatellite ... Metastasis From... Squamous Cell C... Metastasis From... Metastatic Rena... Metastasis From... Metastatic Trip... Metastatic NSCL... Metastasis From... | NBTXR3 SABR Nivolumab Pembrolizumab | 18 Years - | Nanobiotix | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | NCT05478538 | Non Small Cell ... Metastatic Non ... NSCLC Metastatic NSCL... | Core Needle or ... | 18 Years - | Elephas | |
| Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC) | NCT01083589 | Non-small Cell ... | Imatinib Mesyla... Docetaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC | NCT02175381 | NSCLC | Carboplatin Gemcitabine | 70 Years - | Hellenic Oncology Research Group | |
| Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer | NCT05403385 | Metastatic NSCL... Stage III NSCLC | inupadenant Placebo Carboplatin Pemetrexed | 18 Years - | iTeos Therapeutics | |
| Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer | NCT01438307 | Non-small Cell ... Stage IV NSCLC Metastatic NSCL... | Cabazitaxel-XRP... Cabazitaxel-XRP... | 19 Years - | University of Alabama at Birmingham |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
